BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 2011;26:2085-8. [DOI: 10.1007/s00467-011-1989-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Greenbaum LA. Atypical Hemolytic Uremic Syndrome. Advances in Pediatrics 2014;61:335-56. [DOI: 10.1016/j.yapd.2014.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013;28:827-30. [PMID: 23389237 DOI: 10.1007/s00467-013-2416-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
3 Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y. La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques. La Revue de Médecine Interne 2015;36:328-38. [DOI: 10.1016/j.revmed.2014.10.364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
4 Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12:3337-3354. [PMID: 22958221 DOI: 10.1111/j.1600-6143.2012.04252.x] [Cited by in Crossref: 181] [Cited by in F6Publishing: 155] [Article Influence: 18.1] [Reference Citation Analysis]
5 Kim JJ, Waller SC, Reid CJ. Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 2012;5:34-6. [PMID: 26069744 DOI: 10.1093/ndtplus/sfr174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
6 Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 2012;27:2327-31. [PMID: 22903728 DOI: 10.1007/s00467-012-2283-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
8 Cho H. Complement regulation: physiology and disease relevance. Korean J Pediatr 2015;58:239-44. [PMID: 26300937 DOI: 10.3345/kjp.2015.58.7.239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
9 Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. [PMID: 26880462 DOI: 10.1016/j.kint.2015.11.026] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 23.5] [Reference Citation Analysis]
10 Nayer A, Asif A. Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther. 2016;23:e151-e158. [PMID: 24681522 DOI: 10.1097/mjt.0b013e31829b59dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
11 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
12 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61:289-299. [PMID: 23141475 DOI: 10.1053/j.ajkd.2012.07.028] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.0] [Reference Citation Analysis]
14 Udagawa T, Motoyoshi Y, Matsumura Y, Takei A, Ariji S, Ito E, Chiga M, Nagasawa M, Morio T, Mizutani S. Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies. CEN Case Rep 2014;3:110-7. [PMID: 28509254 DOI: 10.1007/s13730-013-0097-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
16 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Asif A, Haqqie SS, Ghate K, Mathew RO, Vachharajani T, Nayer A. Continued Eculizumab Therapy for Persistent Atypical Hemolytic Uremic Syndrome. TOUNJ 2013;6:46-8. [DOI: 10.2174/1874303x01306010046] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
19 Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-72. [PMID: 25173358 DOI: 10.1007/s00467-014-2944-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
20 Blatt J, Corey SJ. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov Today 2013;18:4-10. [PMID: 22835502 DOI: 10.1016/j.drudis.2012.07.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
21 Ricklin D, Lambris JD. Progress and Trends in Complement Therapeutics. Adv Exp Med Biol 2013;735:1-22. [PMID: 22990692 DOI: 10.1007/978-1-4614-4118-2_1] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
22 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
23 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
24 Carter CE, Benador NM. Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol 2014;29:35-50. [PMID: 23812351 DOI: 10.1007/s00467-013-2479-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
25 Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, Sharma S, Cai Y, Ingraham S, Winnicki E, Weaver DJ, Hunley TE, Kiessling SG, Seamon M, Woroniecki R, Miyashita Y, Xiao N, Omoloja AA, Kizilbash SJ, Mansuri A, Kallash M, Yu Y, Sherman AK, Srivastava T, Nester CM. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021;36:2349-60. [PMID: 33693990 DOI: 10.1007/s00467-021-04965-5] [Reference Citation Analysis]
26 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
27 Menne J, Kielstein J, Wenzel U, Stahl R. Therapie des typischen hämolytisch-urämischen Syndroms: Erkenntnisse aus dem E.-coli-Ausbruch 2011. Internist 2012;53:1420-30. [DOI: 10.1007/s00108-012-3107-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kaplan BS, Ruebner RL, Copelovitch L. Eculizumab treatment of atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.750579] [Reference Citation Analysis]
29 Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P. Atypical aHUS: State of the art. Mol Immunol. 2015;67:31-42. [PMID: 25843230 DOI: 10.1016/j.molimm.2015.03.246] [Cited by in Crossref: 162] [Cited by in F6Publishing: 136] [Article Influence: 23.1] [Reference Citation Analysis]
30 Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:783-9. [DOI: 10.1007/s00467-014-3003-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
31 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
32 Anastaze Stelle K, Gonzalez E, Wilhelm-Bals A, Michelet PR, Korff CM, Parvex P. Successful treatment of neonatal atypical hemolytic uremic syndrome with C5 monoclonal antibody. Arch Pediatr 2016;23:283-6. [PMID: 26775886 DOI: 10.1016/j.arcped.2015.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Fremeaux-Bacchi V. Treatment of atypical uraemic syndrome in the era of eculizumab. Clin Kidney J 2012;5:4-6. [PMID: 26069738 DOI: 10.1093/ckj/sfr177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
34 Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 2012;35:394-400. [PMID: 22517061 DOI: 10.1159/000337954] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
35 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
36 Gale DP, Maxwell PH. C3 glomerulonephritis and CFHR5 nephropathy. Nephrology Dialysis Transplantation 2013;28:282-8. [DOI: 10.1093/ndt/gfs441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
37 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]